A Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Latest Information Update: 19 May 2022
At a glance
- Drugs Ublituximab (Primary) ; Lenalidomide
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 05 May 2022 Status changed from completed to discontinued.
- 12 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.